E-Therapeutics plc (ETX)
XSTU
8.12
+0.13 (+1.69%)
Closed
Oct 9, 2026
Day's Range
7.958.16
52 wk Range
4.4111.43
Financial Statements - ETX - E-Therapeutics plc
Revenue
577.52M▼ 28.6%
Net Income
428.24M▲ 73.7%Net Margin 74.2%
EBITDA
253.30M▼ 25.1%
Free Cash Flow
-21.72M▼ 116.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 577.52M | 808.38M | 682.15M | 576.63M | 499.66M | 329.74M |
| Cost of Goods | 282.46M | 400.56M | 282.67M | 146.76M | 187.02M | 245.76M |
| Gross Profit | 295.05M | 407.82M | 399.48M | 429.87M | 312.63M | 83.98M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 141.37M | 255.98M | 253.22M | 302.46M | 172.55M | -22.44M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 389.38M | 235.45M | 172.98M | 280.39M | 141.69M | -544.81M |
| Income Tax | 117.15M | 96.76M | 131.20M | 123.99M | 43.67M | 29.49M |
| Net Income | 428.24M | 246.47M | 242.08M | 175.49M | 120.95M | -591.87M |
| EPS Basic | 2.06 | 1.171859 | 1.06 | 1.03 | 0.61 | -2.99 |
| EPS Diluted | 2.05 | 1.171859 | 1.05 | 1.03 | 0.61 | -2.99 |
| Basic Shares Outstanding | 199.53M | 198.82M | 198.61M | 168.76M | 204.71M | 204.71M |
| Diluted Shares Outstanding | 199.53M | 198.82M | 198.61M | 168.76M | 204.71M | 204.71M |
| Ebit | 405.94M | 253.78M | 195.99M | 296.56M | 155.93M | -529M |
| Ebitda | 253.30M | 338.38M | 382.47M | 370.09M | 279.46M | 577.79M |
| Net Income Continuous Operations | 428.24M | 246.47M | 242.08M | 175.49M | 120.95M | -591.87M |
| Minority Interests | -18.16M | -13.29M | -31.89M | -1.07M | -1.22M | 2.89M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
